Cargando…

Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis

In March 2012, in response to reports of tuberculosis (TB) resistant to all anti-TB drugs, the World Health Organization convened an expert consultation that identified issues to be resolved before defining a new category of highly drug-resistant TB. Proposed definitions are ambiguous, and extensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cegielski, Peter, Nunn, Paul, Kurbatova, Ekaterina V., Weyer, Karin, Dalton, Tracy L., Wares, Douglas F., Iademarco, Michael F., Castro, Kenneth G., Raviglione, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559144/
https://www.ncbi.nlm.nih.gov/pubmed/23092736
http://dx.doi.org/10.3201/eid1811.120526
_version_ 1782257516363644928
author Cegielski, Peter
Nunn, Paul
Kurbatova, Ekaterina V.
Weyer, Karin
Dalton, Tracy L.
Wares, Douglas F.
Iademarco, Michael F.
Castro, Kenneth G.
Raviglione, Mario
author_facet Cegielski, Peter
Nunn, Paul
Kurbatova, Ekaterina V.
Weyer, Karin
Dalton, Tracy L.
Wares, Douglas F.
Iademarco, Michael F.
Castro, Kenneth G.
Raviglione, Mario
author_sort Cegielski, Peter
collection PubMed
description In March 2012, in response to reports of tuberculosis (TB) resistant to all anti-TB drugs, the World Health Organization convened an expert consultation that identified issues to be resolved before defining a new category of highly drug-resistant TB. Proposed definitions are ambiguous, and extensive drug resistance is encompassed by the already defined extensively drug-resistant (XDR) TB. There is no evidence that proposed totally resistant TB differs from strains encompassed by XDR TB. Susceptibility tests for several drugs are poorly reproducible. Few laboratories can test all drugs, and there is no consensus list of all anti-TB drugs. Many drugs are used off-label for highly drug resistant TB, and new drugs formulated to combat resistant strains would render the proposed category obsolete. Labeling TB strains as totally drug resistant might lead providers to think infected patients are untreatable. These challenges must be addressed before defining a new category for highly drug-resistant TB.
format Online
Article
Text
id pubmed-3559144
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-35591442013-02-04 Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis Cegielski, Peter Nunn, Paul Kurbatova, Ekaterina V. Weyer, Karin Dalton, Tracy L. Wares, Douglas F. Iademarco, Michael F. Castro, Kenneth G. Raviglione, Mario Emerg Infect Dis Online Report In March 2012, in response to reports of tuberculosis (TB) resistant to all anti-TB drugs, the World Health Organization convened an expert consultation that identified issues to be resolved before defining a new category of highly drug-resistant TB. Proposed definitions are ambiguous, and extensive drug resistance is encompassed by the already defined extensively drug-resistant (XDR) TB. There is no evidence that proposed totally resistant TB differs from strains encompassed by XDR TB. Susceptibility tests for several drugs are poorly reproducible. Few laboratories can test all drugs, and there is no consensus list of all anti-TB drugs. Many drugs are used off-label for highly drug resistant TB, and new drugs formulated to combat resistant strains would render the proposed category obsolete. Labeling TB strains as totally drug resistant might lead providers to think infected patients are untreatable. These challenges must be addressed before defining a new category for highly drug-resistant TB. Centers for Disease Control and Prevention 2012-11 /pmc/articles/PMC3559144/ /pubmed/23092736 http://dx.doi.org/10.3201/eid1811.120526 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Online Report
Cegielski, Peter
Nunn, Paul
Kurbatova, Ekaterina V.
Weyer, Karin
Dalton, Tracy L.
Wares, Douglas F.
Iademarco, Michael F.
Castro, Kenneth G.
Raviglione, Mario
Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title_full Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title_fullStr Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title_full_unstemmed Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title_short Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis
title_sort challenges and controversies in defining totally drug-resistant tuberculosis
topic Online Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559144/
https://www.ncbi.nlm.nih.gov/pubmed/23092736
http://dx.doi.org/10.3201/eid1811.120526
work_keys_str_mv AT cegielskipeter challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT nunnpaul challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT kurbatovaekaterinav challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT weyerkarin challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT daltontracyl challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT waresdouglasf challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT iademarcomichaelf challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT castrokennethg challengesandcontroversiesindefiningtotallydrugresistanttuberculosis
AT raviglionemario challengesandcontroversiesindefiningtotallydrugresistanttuberculosis